Sugi Predict

Sugi Predict / Targets / DUSP23

DUSP23

Dual specificity protein phosphatase 23 · Q9BVJ7 · DUSP23 on Sugi Atlas →

100 patent compounds predicted against DUSP23, 97 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13736685 SCHEMBL13736685 1.00 2/20
SCHEMBL15829189 SCHEMBL15829189 1.00 2/20
SCHEMBL18230879 SCHEMBL18230879 0.81 2/20
SCHEMBL15829194 SCHEMBL15829194 0.80 2/20
SCHEMBL15829188 SCHEMBL15829188 0.78 2/20
SCHEMBL15829190 SCHEMBL15829190 0.78 2/20
SCHEMBL15829193 SCHEMBL15829193 0.77 2/20
SCHEMBL18230880 SCHEMBL18230880 0.76 2/20
SCHEMBL15829191 SCHEMBL15829191 0.75 2/20
SCHEMBL15829185 SCHEMBL15829185 0.67 2/20
SCHEMBL18230877 SCHEMBL18230877 0.67 2/20
SCHEMBL18231230 SCHEMBL18231230 0.66 2/20
SCHEMBL15829192 SCHEMBL15829192 0.65 2/20
SCHEMBL15829168 SCHEMBL15829168 0.65 2/20
SCHEMBL15829166 SCHEMBL15829166 0.62 2/20
SCHEMBL15829167 SCHEMBL15829167 0.60 2/20
SCHEMBL15829187 SCHEMBL15829187 0.59 2/20
SCHEMBL15829172 SCHEMBL15829172 0.58 2/20
SCHEMBL15829183 SCHEMBL15829183 0.57 2/20
SCHEMBL15829184 SCHEMBL15829184 0.53 2/20

Clinical trials — most relevant to DUSP23 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Treatment With HMG-COA Reductase Inhibitor of Growth and Bone Abnormalities in Children With Noonan Syndrome PHASE3COMPLETED
Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer PHASE2COMPLETED
Everolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer PHASE2COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes PHASE2COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion PHASE2ACTIVE_NOT_RECRUITING
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome PHASE1COMPLETED
A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL) PHASE1COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors PHASE1WITHDRAWN
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
Genetic Identification (ID) of Segmental Dysplastic Nevi nanWITHDRAWN
NGS in Gallbladder Cancer and Response to Treatment nanRECRUITING
Quantification of GADD34 Expression in RA nanCOMPLETED
Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing nanRECRUITING
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
RASopathy Biorepository nanRECRUITING
Studies of the Tumour Suppressor Gene PTEN - Endometrial Cancer nanCOMPLETED
Partial PTEN Deletion in Breast Cancer nanUNKNOWN
Identification of Novel Targetable Kinases in SR-a GvHD nanCOMPLETED
Molecular Mechanisms Underlying Prostate Cancer Disparities nanCOMPLETED
Exome Sequencing for Atypical Femoral Fractures nanCOMPLETED
Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane nanUNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a DUSP23 binder may also engage these)

ProteinNameSimilarity
Q6NT99 — 1.000 Q6NT99 →
Q17QM8 — 0.950 Q17QM8 →
Q9D7X3 — 0.948 Q9D7X3 →
Q5RD73 — 0.948 Q5RD73 →
Q9JLY7 — 0.946 Q9JLY7 →
AMDHD2 N-acetylglucosamine-6-phosphate deacetylase 0.945 landscape →
DUSP3 Dual specificity protein phosphatase 3 0.945 landscape →
Q2IJJ5 — 0.945 Q2IJJ5 →
O95147 — 0.945 O95147 →
A4JKV8 — 0.944 A4JKV8 →
Q9WVS2 — 0.944 Q9WVS2 →
Q5RCH4 — 0.944 Q5RCH4 →
O95396 — 0.944 O95396 →
Q9NZC7 — 0.943 Q9NZC7 →
OSGEP tRNA N6-adenosine threonylcarbamoyltransferase 0.943 landscape →
P53607 — 0.943 P53607 →
Q67NB6 — 0.943 Q67NB6 →
A0AAT9JA24 — 0.943 A0AAT9JA24 →
Q5R9W5 — 0.942 Q5R9W5 →
A9AQJ3 — 0.942 A9AQJ3 →
Q59699 — 0.942 Q59699 →
Q14BV6 — 0.942 Q14BV6 →
Q98AM7 — 0.941 Q98AM7 →
Q4UXV5 — 0.941 Q4UXV5 →
Q8PHK1 — 0.941 Q8PHK1 →
Q8BK84 — 0.941 Q8BK84 →
Q39IE7 — 0.941 Q39IE7 →
B4EJA6 — 0.941 B4EJA6 →
Q62M41 — 0.941 Q62M41 →
Q9DCM0 — 0.941 Q9DCM0 →